Karolinska Development's portfolio company OssDsign includes first patient to a clinical trial of the synthetic bone graft OssDsign Catalyst
September 09 2021 - 2:00AM
Karolinska Development's portfolio company OssDsign includes first
patient to a clinical trial of the synthetic bone graft OssDsign
Catalyst
STOCKHOLM, SWEDEN – September 9, 2021. Karolinska Development AB
(Nasdaq Stockholm: KDEV) announces today that the portfolio company
OssDsign AB has included the first patient to the clinical trial
TOP FUSION which aims to evaluate the long-term safety and efficacy
of the synthetic bone graft OssDsign Catalyst in patients
undergoing spinal fusion surgery.
The clinical trial will run for 24 months and include 17
patients suffering from degenerative disc disease, degenerative
spondylolisthesis or lumbar spinal stenosis. TOP FUSION is being
conducted primarily to evaluate the safety and efficacy of OssDsign
Catalyst in patients undergoing spinal fusion surgery. Study
outcomes are based primarily on the degree of fusion between the
vertebrae and the incidence of treatment-related adverse events.
The innovative bone graft consists of a patented nanocrystalline
structure that is applied to the spine where it resorbs and is
replaced by new bone tissue.
The study is conducted under the leadership by Dr Péter Pál
Varga and Dr Áron Lazary, internationally renowned physicians and
researchers in spine surgery at the National Center for Spinal
Disorders at the Buda Health Clinic in Budapest. Dr Varga is the
founder of the specialist center where more than 2,500 spine
surgeries are performed annually.
“This is an important next step in the further validation of
OssDsign Catalyst. Once again, OssDsign shows that they step by
step are delivering on the commercialization plan set up for its
innovative synthetic bone graft which was recently launched in the
US,” comments Viktor Drvota, CEO, Karolinska Development AB.
Karolinska Development's shareholding in OssDsign AB, including
an indirect ownership via KCIF Co-Investment Fund, amounts to 10
per cent.
For further information, please
contact:
Viktor Drvota, CEO, Karolinska Development AB Phone: +46 73 982
52 02, e-mail: viktor.drvota@karolinskadevelopment.com
Johan Dighed, General Counsel and Deputy CEO, Karolinska
Development ABPhone: +46 70 207 48 26, e-mail:
johan.dighed@karolinskadevelopment.com
TO THE EDITORS
About Karolinska Development ABKarolinska
Development AB (Nasdaq Stockholm: KDEV) is a Nordic life sciences
investment company. The company focuses on identifying breakthrough
medical innovations in the Nordic region that are developed by
entrepreneurs and leadership teams. The Company invests in the
creation and growth of companies that advance these assets into
commercial products that are designed to make a difference to
patients' lives while providing an attractive return on investment
to shareholders.
Karolinska Development has access to world-class medical
innovations at the Karolinska Institutet and other leading
universities and research institutes in the Nordic region. The
Company aims to build companies around scientists who are leaders
in their fields, supported by experienced management teams and
advisers, and co-funded by specialist international investors, to
provide the greatest chance of success.
Karolinska Development has a portfolio of ten companies
targeting opportunities in innovative treatment for
life-threatening or serious debilitating diseases.
The Company is led by an entrepreneurial team of investment
professionals with a proven track record as company builders and
with access to a strong global network.
For more information, please visit
www.karolinskadevelopment.com.
- PM KD OssDsign FPI Top Fusion ENG 2021-09-09
Karolinska Development Ab (LSE:0P3C)
Historical Stock Chart
From Mar 2024 to Apr 2024
Karolinska Development Ab (LSE:0P3C)
Historical Stock Chart
From Apr 2023 to Apr 2024